DOI: 10.5061/dryad.fttdz093t
title: Data from: Serum proteome characterizes sequence of CNS injury in pre-symptomatic multiple sclerosis

description: The timing of the biological onset of multiple sclerosis (MS) is unclear.
 We utilized high-throughput discovery proteomics and samples from
 pre-symptomatic individuals with MS (pwMS) and matched healthy controls
 (HC) to define the biological neurological onset and characterize involved
 mechanisms. Remarkably, myelin injury was seen 7-8 years before the
 symptomatic onset and preceded evidence of axonal injury by 1-2 years. By
 contrast, astrocyte involvement became evident only at clinical onset.
 Numerous changes in the serum proteome indicate the involvement of
 interleukin 3 and nuclear factor kappa B pathways during the
 pre-symptomatic stage. A protein biomarker panel identified
 pre-symptomatic pwMS from HC with 95% sensitivity. Additionally, pwMS with
 a distinct autoantibody signature showed increased immune cell activity
 compared to those without. Our findings can help decipher the
 pathophysiology of MS as well as the cascade of CNS injury and facilitate
 early detection of MS in high-risk individuals.
description: # Data from: Serum proteome characterizes sequence of CNS injury in
 pre-symptomatic multiple sclerosis
 [https://doi.org/10.5061/dryad.fttdz093t](https://doi.org/10.5061/dryad.fttdz093t) ## Description of the data and file structure Proteomic data were generated from serum collected from selected participants of the Department of Defense Serum Repository. Participants included people who developed multiple sclerosis and matched healthy controls. Data generated on the Olink platform using the Olink Explore HT kit. For an in-depth description of the participant selection and data processing, see the related manuscript. ### Files and variables #### File: dodsr.ms.proteomics.csv **Description:** .csv file containing basic demographics and clinical data, as well as Olink measurements from all included participants from the Department of Defense Serum Repository ##### Variables * StudyID: anonymized participant ID * timepoint: time point in relation to symptomatic multiple sclerosis onset, either "pre" or "post" indicating before or after the symptomatic onset of the disease, respectively * sample_year: sample collection year * ms_vs_hc: diagnosis assigned into multiple sclerosis "ms" or healthy controls "hc" * time_to_onset: time between sample collection and symptomatic multiple sclerosis onset in years. Negative values indicate sample collection before symptomatic disease onset.  * sex: biological sex, either male "M", or female "F" * assay: Olink assay name * age_sample: age of participant at the time of sample collection * npx: Normalized Protein eXpression * immunecluster: Presense "yes" or abscence "no" of autoantibody sigature * assay_qc: Assay performance quality control, values are either "PASS" or "WARN" * sample_qc: Sample performance quality control, values are either "PASS" or "WARN" ## Access information Other publicly accessible locations of the data: * NA Data was derived from the following sources: * NA ## Human subjects data All participant IDs, datasets, and samples were fully anonymized by the Department of Defense Serum Repository (DODSR) staff prior to being provided for this research. As a result, the dataset received and subsequently uploaded contains no personally identifiable information (PII). This study was reviewed and approved by both the Office of Human Research Oversight (OHRO), U.S. Army Medical Research and Development Command (USAMRDC), and the University of California, San Francisco (UCSF) Institutional Review Board (IRB).